Jason B.
About Jason B.
Jason B. is a Principal Scientist at ORIC Pharmaceuticals, where he oversees DMPK activities and manages outsourced projects related to drug development. He specializes in small molecule therapeutics for neurodegenerative diseases and has extensive experience in pharmacokinetic assessment and drug disposition kinetics.
Work at ORIC Pharmaceuticals
Jason B. has been serving as Principal Scientist at ORIC Pharmaceuticals since 2020. In this role, he oversees and reviews drug metabolism and pharmacokinetics (DMPK) activities to facilitate the advancement of drug development programs. He also manages outsourced projects related to DMPK, ensuring that all activities align with the company's strategic goals. His focus includes supporting the development of small molecule therapeutics aimed at treating neurodegenerative diseases.
Previous Experience in Drug Development
Before joining ORIC Pharmaceuticals, Jason B. worked as a Senior Scientist at ESCAPE Bio from 2019 to 2020 in South San Francisco, California. He also held the position of Scientist (Study Director) at Optivia Biotechnology from 2013 to 2016 in the San Francisco Bay Area. His earlier experience includes a role as a Postdoctoral Fellow at UCSF from 2012 to 2013 and as a Commissioned Research Scientist at the Korea Institute of Science and Technology in 2005 to 2006.
Education and Expertise
Jason B. holds a Ph.D. in Pharmaceutical Sciences from the University of Michigan, where he studied from 2006 to 2012. He also completed a Postdoctoral Fellowship at UCSF from 2012 to 2014. His undergraduate education includes a Bachelor of Science in Materials (Polymer) Sciences and Engineering from Seoul National University, completed from 1999 to 2005. His expertise includes the translation of drug disposition kinetics from in vitro, in vivo, and in silico assessments, as well as utilizing LCMS for pharmacokinetic assessment and bioanalysis.
Research Contributions
Throughout his career, Jason B. has contributed to various research initiatives in the field of drug development. His work has involved overseeing DMPK activities and managing projects that support the development of therapeutics for neurodegenerative diseases. His experience spans multiple organizations and roles, allowing him to build a comprehensive understanding of drug disposition and pharmacokinetics.